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INTRODUCTION 
 
   Diabetes Mellitus is in the potential epidemic state in 
India and referred to as the diabetic capital of the world. Diabetes 
mellitus is more prevalent in our nation and its incidence rate is 
increasing in alarming proportions. Over the past 2 decades, prevalence 
of diabetes mellitus in the world wide has increasing dramatically, from 
an estimated 30 million cases in 1985 to 177 million cases in 2000. As on 
current data, by the year 2030 more than 360 million people in worldwide 
will have diabetes mellitus. Although the prevalence of both the types of 
diabetes mellitus is increasing worldwide, the prevalence of type 2 
diabetes mellitus is much more rapidly rising than other types due to 
more of obesity and sedentary lifestyle as countries become more 
industrialized. Worldwide estimates project that more number of 
individuals with diabetes mellitus will be in the age group of 45–64 years 
in 2030. 
 
  As per to the Diabetes Atlas published by the International 
Diabetes Federation (IDF), In India, there are an estimated 40 million 
people with diabetes mellitus  in 2007 ,has risen to 60 million in 2009 and 
it is predicted to rise about 120 million people in 2025 by which time 
every 5th  diabetic person  in the world would be an Indian. Diabetes 
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mellitus is one of the major cause of morbidity and mortality, but 
numerous studies indicate that diabetes is likely under reported as a cause 
of death. A recent estimate suggested that diabetes was the fifth leading 
cause of death worldwide and was responsible for almost 3 million deaths 
annually (1.7–5.2% of deaths worldwide).  
 
  Diabetes mellitus is the most common cause of kidney 
failure2, accounting for around 44 percent of new cases. It is a detrimental 
condition in which the renal system fails to clear the body of wastes. 
Kidney failure is the last stage of chronic kidney disease (CKD). Even 
though when diabetes mellitus is controlled, it can progress to CKD and 
kidney failure. Many number of people with diabetes mellitus do not 
develop CKD that is severe enough to progress to kidney failure. There 
are many number of factors3 that interplay leading to kidney disease in 
diabetes mellitus which include genetic, diet, and other medical diseases, 
such as Hypertension. It has been documented in several studies that 
higher the blood pressure and plasma glucose levels, more the risk and 
progress to kidney failure. So there is a need to diagnose subnormal 
kidney function4 at an earlier stage in order to initiate treatment to 
prevent the progression of kidney damage. 
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   Glucose tolerance test (GTT) has been used to diagnosis the 
diabetes mellitus in patients who are at risk. The stress of glucose load in 
GTT unravels the patient with marginal pancreatic dysfunction. It has 
been suggested that similar to GTT, a protein tolerance test (PTT) may 
helpful to diagnose the individuals with subnormal renal function before 
the disease manifestation. Raising creatinine level is often considered the 
first sign of a real dysfunction, but now, it may not be so. 
Microalbuminuria, another test to diagnose early renal dysfunction and it 
has been used as a marker of endothelial dysfunction at present. By the 
time the serum creatinine levels increase, a good amount of irreversible 
kidney damage is done .so, now this stresses the need for the tolerance 
test on the kidney in patients who have low glomerular filtration rate. 
 
  An acute oral protein load causes a transient hyper filtration 
that might reveal a loss of glomerular permeability properties .So, acute 
protein load test is of great utility in revealing a silent glomerular 
filtration disturbance. 
 
  The stress of PTT will enable us to determine individuals 
with impaired functional reserve. The present study utilizes this principle 
to identify those patients with diabetes who are at risk of developing renal 
failure. 
13 
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AIM OF THE STUDY: 
 
1. To evaluate the usefulness of “Protein tolerance Test” as a method 
of measuring renal functional reserve & diagnose early renal 
dysfunction in       Type 2 diabetes. 
 
2.  To compare the above with normal subjects 
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REVIEW OF LITERATURE 
DIABETES MELLITUS 
“Diabetes mellitus refers to a group of metabolic disorders causing 
hyperglycemia due to reduced insulin secretion or action or both and 
increased production and /or decreased glucose utilization.” The 
metabolic derangement associated with Diabetes mellitus causes various 
complications that impose a huge burden to the individual, health care 
system and the country.5 
CLASSIFICATION 
Diabetes Mellitus can be classified into the following 4 major 
categories:- 
“1. Type 1 Diabetes Mellitus (due to Pancreatic Beta cell destruction 
leading to absolute insulin deficiency)  
2. Type 2 diabetes Mellitus (due to predominantly resistance with relative 
insulin deficiency) 
3. Gestational Diabetes Mellitus (diagnosed first time during pregnancy 
in a previously non diabetic individuals)  
4. Other Specific types of diabetes (due to some other causes)” 
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Table.1 Etiologic Classification of Diabetes Mellitus: 
 
“I. Type 1 Diabetes Mellitus 
a) Immune-mediated              b) Idiopathic 
II. Type 2 Diabetes Mellitus 
III. Gestational diabetes mellitus  
IV. Other specific types of diabetes: 
A. Genetic defects of beta cell development or function characterized by    
mutations in:  
1. Hepatocyte nuclear transcription factor (HNF) 4α (MODY 1) 
2. Glucokinase (MODY 2) 
3. HNF-1α (MODY 3) 
4. Insulin promoter factor-1 (IPF-1; MODY 4) 
5. HNF-1β (MODY 5) 
6. NeuroD1 (MODY 6) 
7.Proinsulin or insulin  
8. Mitochondrial DNA 
9. Subunits of ATP-sensitive potassium channel 
10.Other pancreatic islet regulators/proteins such as KLF11, PAX4, BLK, GATA4, 
GATA6, SLC2A2 (GLUT2), RFX6, GLIS3  
        B. Genetic defects in insulin action: 
               1. Type A insulin resistance 
               2. Leprechaunism 
               3. Rabson-Mendenhall syndrome 
               4. Lipodystrophy syndromes 
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C. Diseases of the exocrine pancreas—pancreatitis, fibro calculous 
pancreatopathy, pancreatectomy, cystic  fibrosis, hemochromatosis, neoplasia, 
mutations in carboxyl ester lipase 
 
D. Endocrinopathies—acromegaly, pheochromocytoma, aldosteronoma 
,glucagonoma ,Cushing’s syndrome, hyperthyroidism, somatostatinoma,  
 
E. Drug- or chemical-induced—glucocorticoids, β-adrenergic agonists, 
vacor (a rodenticide), pentamidine, nicotinic acid, diazoxide, thiazides, 
calcineurin and mTOR inhibitors, protease inhibitors ,epinephrine ,hydantoins, 
asparaginase, α-interferon, , antipsychotics (atypical and others). 
 
F. Infections— coxsackievirus, congenital rubella, cytomegalovirus,  
 
G. Uncommon forms of immune-mediated diabetes—stiff-person 
syndrome, anti-insulin receptor antibodies 
 
H. Other genetic syndromes sometimes associated with diabetes— 
Klinefelter’s syndrome, Down’s syndrome, Wolfram’s syndrome, Turner’s 
syndrome, Friedreich’s ataxia, Huntington’s chorea, porphyria, Laurence-
MoonBiedl syndrome, Prader-Willi syndrome ,myotonic dystrophy.” 
Abbreviation: MODY, maturity-onset diabetes of the young 
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Type 2 DM is preceded by a period of abnormal glucose 
homeostasis classified as “impaired fasting glucose” (IFG) or “impaired 
glucose tolerance (IGT)” .These group of patients categorized as 
increased risk for diabetes or Pre diabetes or intermediate hyperglycemia. 
 
Fig. 1 Spectrum of glucose homeostasis and Diabetes Mellitus5  
 
 
-Values not applicable to the diagnosis of gestational DM. 
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DIAGNOSIS OF DIABETES MELLITUS 
  “Diagnosis of Diabetes is made by the following criteria5 
approved by American Diabetes association 2014. 
Table 2. Diagnostic criteria of diabetes mellitus5 
HbA1C                                                              (or) ≥ 6.5%. 
Fasting Plasma Glucose                                    (or) ≥126 mg/dL 
2-h Plasma Glucose during an OGTT              (or) ≥200 mg/dL 
Random plasma glucose 
(In a patient with classic symptoms of hyperglycemia or 
hyperglycaemic crisis) 
≥200 mg/dL” 
 
 
Prerequisites for Testing:  
 “HbA1C test should be performed by the method that is NGSP 
certified and standardized to the DCCT assay. 
 Fasting is defined as no caloric intake for at least 8 h. 
 OGTT should be performed using a glucose load equivalent of 75g  
of anhydrous glucose dissolved in water , as described by the 
WHO, 
 Random is defined as without regard to time since the last meal. 
 In the absence of unequivocal hyperglycemia, diagnosis should be 
confirmed by repeat testing.” 
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PATHOPHYSIOLOGY OF TYPE 2  DIABETES MELLITUS 
 
 
  Type 2 DM is characterized by “predominantly insulin 
resistance, impaired insulin secretion, hepatic gluconeogenesis, and 
abnormal lipid metabolism. Obesity, particularly visceral or central (as 
evidenced by the waist-hip ratio), is very common in type 2 DM (≥80% 
of patients are obese). In the early stages of the disorder, glucose 
tolerance remains near normal, despite insulin resistance, because the 
pancreatic beta cells compensate by increasing insulin output. As insulin 
resistance and compensatory hyperinsulinemia progress, the pancreatic 
islets in certain individuals are unable to sustain the hyperinsulinemic 
state. IGT, characterized by elevations in postprandial glucose, then 
develops. A further decline in insulin secretion and an increase in hepatic 
glucose production lead to overt diabetes with fasting hyperglycemia. 
Ultimately, beta cell failure ensues. Although both insulin resistance and 
impaired insulin secretion contribute to the pathogenesis of type 2 DM, 
the relative contribution of each varies from individual to individual.” 
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Fig.2. Natural Progression of diabetes Mellitus5 
 
 
  In Fig.3, “Insulin secretion and insulin sensitivity are related, 
and as an individual becomes more insulin resistant (by moving from 
point A to point B), insulin secretion increases. A failure to compensate 
by increasing the insulin secretion results initially in impaired glucose 
tolerance (IGT; point C) and ultimately in type 2 DM (point D).” 
NGT-normal glucose tolerance. 
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Fig. 3 Metabolic changes during the development of Type 2 DM   
 
 
 
OMINOUS OCTET:  
 
  Finally and the most important, player to be implicated in 
the pathogenesis of type 2 diabetes mellitus is “the brain, which, along 
with his seven companions, forms the ominous octet”.45 
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Fig. 4 Ominous Octet  
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COMPLICATIONS OF DIABETES MELLITUS:  
Table 3 .Complications of Diabetes 
 
“ACUTE COMPLICATIONS:  
 
a) Hypoglycemia 
b) Diabetic Keto Acidosis (DKA) 
c) Hyperglycaemic Hyper osmolar state (HHS) 
 
CHRONIC COMPLICATIONS: 
 
Microvascular: 
 Nephropathy 
 Retinopathy 
 Neuropathy  
 
Macrovascular: 
 Coronary Artery Disease( CAD )  
 Cerebro Vascular Disease (CVD) 
 Peripheral Artery Disease (PAD)  
 
Others: 
 GIT: (Gastroparesis, diarrhoea) 
 Uropathy/sexual dysfunction) 
 Dermatologic 
 Infectious 
 Cataracts, Glaucoma 
 Cheiroarthropathy 
 Periodontal disease 
 Hearing loss” 
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DIABETIC NEPHROPATHY 
  The natural history of Diabetic Nephropathy in patients with 
type 2 DM is less well understood than in patients with type 1 DM. This 
partly reflects the fact that type 2 DM is largely a disease of an older 
population with associated obesity ,hypertension ,dyslipidemia and high 
rates of cardiovascular disease that restrict the manifestation of renal 
disease. In addition approximately 7% of the patients with type 2 DM 
already have microalbuminuria at the time of diagnosis. Within 5 years of 
diagnosis 18% have microalbuminuria especially those with poor 
metabolic control and high blood pressure levels8. 
 
  It is commoner to see more patients of type 2 DM with 
nephropathy than those with type 1 DM (9:1) even though the incidence 
of nephropathy is high in type 1 DM (30%) when compared to type 2 DM 
(20%) 9 
 
DEFINITION: 
  Nephropathy is one of the commonest complications of type 
2 diabetes mellitus. “Diabetic nephropathy10 (DN) is typically defined by 
macro albuminuria i.e. urinary albumin excretion of more than 300 mg in 
a 24-hour collection and abnormal renal function as represented by an 
abnormality in serum creatinine, calculated creatinine clearance, or 
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glomerular filtration rate (GFR).” Clinically, it is characterized by a 
progressive increase in proteinuria and progressive decline in GFR, 
hypertension, and a high risk of cardiovascular morbidity and mortality11. 
 
PREVALENCE:  
  Diabetes has become the major cause of end-stage renal 
disease (ESRD) and the incidence of type 2 diabetes mellitus is abruptly 
increasing worldwide. “Approximately 44% of new patients entering 
dialysis in the United States are diabetics12 and 20% to 30% of all 
diabetics will develop evidence of nephropathy, although a higher 
percentage of type 1 patients progress to ESRD13.” 
 
RISK FACTORS:  
“Risk factors for diabetic nephropathy14 are shown in table 4. 
Table 4 .Risk factors for diabetic nephropathy 
 
 African American, Hispanic, or American Indian origin  
 Family history of kidney disease or high blood pressure  
 Poor control of blood pressure 
 -Poor control of blood glucose 
 Type 1 diabetes before age 20  
 Smoking” 
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PATHOPHYSIOLOGY AND NATURAL HISTORY:  
 
The progression of nephropathy from “microalbuminuria to overt 
nephropathy has led many to consider microalbuminuria to define early 
or incipient nephropathy15.” Renal disease is suspected to be secondary to 
diabetes in the clinical setting of long-standing diabetes. This is supported 
by the history of diabetic retinopathy, particularly in type 1 diabetics, in 
whom there is a strong correlation. 
 
Fig. 5. Natural history of Diabetic Nephropathy 
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  “Early diabetes is heralded by glomerular hyper filtration 
and an increase in GFR. This is believed to be related to increased cell 
growth and expansion in the kidneys, possibly mediated by 
hyperglycemia itself. Microalbuminuria typically occurs after 5 years in 
type 1 diabetes.16 Overt nephropathy, with urinary protein excretion 
higher than 300 mg/day, often develops after 10 to 15 years. ESRD 
develops in 50% of type 1 diabetics, with overt nephropathy within 10 
years. 
 
Fig. 6. Typical Progression of Diabetic Nephropathy 46 
 
30 
 
Fig. 7. Time course of development of Diabetic Nephropathy. 
 
 
  Type 2 diabetes has a more variable course. Patients often 
present at diagnosis with microalbuminuria because of delays in 
diagnosis and other factors affecting protein excretion. Fewer patients 
with microalbuminuria progress to advanced renal disease. Without 
intervention, approximately 30% progress to overt nephropathy and, after 
20 years of nephropathy, approximately 20% develop ESRD. Because of 
the high prevalence of type 2 compared with type 1 diabetes; however, 
most diabetics on dialysis are type 2 diabetics. 
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Long-standing hyperglycemia is known to be a significant risk 
factor for the development of diabetic nephropathy.17 Hyperglycemia 
may directly result in mesangial expansion and injury by an increase in 
the mesangial cell glucose concentration. The glomerular mesangium 
expands initially by cell proliferation and then by cell hypertrophy. 
Increased mesangial stretch and pressure can stimulate this expansion, as 
can high glucose levels.18 
 
Fig. 8. Pathophysiological mechanisms of Diabetic Nephropathy: 
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  Advanced glycosylation end products (AGEs) can form 
complex cross-links over years of hyperglycemia and can contribute to 
renal damage by stimulation of growth and fibrotic factors via receptors 
for AGEs. In addition, mediators of proliferation and expansion, 
including platelet-derived growth factor, TGF-β, and vascular endothelial 
growth factor (VEGF) that are elevated in diabetic nephropathy can 
contribute to further renal and microvascular complications. 
 
  In diabetic nephropathy, the activation of the local renin-
angiotensin system occurs in the proximal tubular epithelial cells, 
mesangial cells, and podocytes. Angiotensin II (ATII) itself contributes to 
the progression of diabetic nephropathy. ATII is stimulated in diabetes 
despite the high-volume state typically seen with the disease, and the 
intrarenal level of ATII is typically high, even in the face of lower 
systemic concentrations. ATII preferentially constricts the efferent 
arteriole in the glomerulus, leading to higher glomerular capillary 
pressures. In addition to its hemodynamic effects, ATII also stimulates 
renal growth and fibrosis through ATII type 1 receptors, which 
secondarily upregulate TGF-β and other growth factors.” 
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Fig . 9.1-9.3 Pathological Features of Diabetic Nephropathy 
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THE COURSE OF KIDNEY DISEASE IN DIABETES 
 
 Diabetic kidney disease takes many years to develop. In some 
people, “the filtering function of the kidneys is actually higher than 
normal in the first few years of their diabetes. Over several years, people 
who are developing kidney disease will have small amounts of the blood 
protein -albumin begin to leak into their urine. This first stage of CKD is 
called microalbuminuria.” The kidney’s filtration function usually 
remains normal during this period. “As the disease progresses, more 
albumin leaks into the urine.25 This stage may be called macro 
albuminuria or proteinuria.” 
 
Fig. 10 Stages of Diabetic Nephropathy according to Urinary 
Albumin level : 
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  “As the amount of albumin in the urine increases, the 
kidneys’ filtering function usually begins to drop. The body retains 
various wastes as filtration falls. As kidney damage develops, blood 
pressure often rises as well. Overall, kidney damage rarely occurs in the 
first 10 years of diabetes, and usually 15 to 25 years will pass before 
kidney failure occurs. For people who live with diabetes for more than 25 
years without any signs of kidney failure, the risk of ever developing it 
decreases. People with diabetes should be screened regularly for kidney 
disease26.” 
DIAGNOSIS OF CKD 
Fig.11 Diagnostic criteria of CKD: 
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Fig.12 Stages of CKD:  
 
 The two key markers for kidney disease are eGFR and urine 
albumin eGFR stands for estimated glomerular filtration rate27. The 
calculation of eGFR is based on the amount of creatinine, a waste 
product, found in a blood sample. As the level of creatinine goes up, the 
eGFR goes down. “Glomerular filtration rate (GFR) measures the amount 
of glomerular filtrate (a substance similar to the plasma part of blood but 
without the proteins) formed in the kidneys per minute. The results help 
indicate the kidney’s ability to filter and remove waste products from the 
body.” 
Types and differences of GFR 
 
The glomerular filtration rate (GFR) of the kidneys cannot be 
directly measured. However, various methods have been developed to 
provide indirect measurements and estimates.30 
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Inulin Clearance Test: 
 “Inulin, a complex fructose sugar is considered an ideal 
filtration marker for the measurement of GFR in humans. Inulin is 
injected into the patient and the amount of inulin filtered at the glomeruli 
(blood vessels in the kidney) normally equals the amount of excreted 
inulin.” However, this method is not often used because it is costly, 
inconvenient and better suited for research studies.  
Radioactive marker clearance test:  
 The use of radioactive markers also provides an accurate 
measurement of GFR.32 However, they are not readily available .  
Serum creatinine and creatinine clearance: 
 It is the most commonly used method to measure the GFR. 
“Creatinine is a waste product that comes from two sources: meat 
products in the diet and muscle use. Almost all creatinine eventually ends 
up in a person’s urine. Creatinine measurements from blood and urine 
samples are used to calculate GFR because the chemical is normally 
present in the body and very little of it is reabsorbed.” 
A creatinine clearance test compares the levels of creatinine in the 
urine and the blood, along with urine volume. A 24-hour urine sample is 
usually collected and a blood sample is taken from a vein, and the 
estimated GFR is calculated. 
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Serum creatinine based prediction equations 
 Serum creatinine based prediction equations are more accurate in 
estimating GFR than serum creatinine measurements alone. The 
equations are useful because they take into consideration that creatinine 
production varies according to age, gender, race or ethnicity, and muscle 
mass.  
Fig.13. Equations to estimate GFR from Creatinine   
 
 
 
 
 
 
 
 
 
 
 
 
 
“The Cockcroft-Gault and Jelliffe were originally developed for 
estimating creatinine clearance. However, they have been widely tested 
as predictors of GFR in adults. 
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A newly developed equation, the MDRD Study equation, also 
provides an estimate of GFR in adults. The abbreviated version of the 
equation is based on serum creatinine concentration, age, gender and race 
and is standardized for body surface area.  
 
There are some drawbacks to using prediction equations. One is 
that the equations are much less accurate at measuring a higher range of 
GFR, such as occurs in a healthy person or in the early stages of chronic 
kidney disease. As a result, other indications of early kidney disease, such 
as proteinuria (abnormally high levels of protein in the urine) are needed 
to detect early deterioration in kidney function. In newly diagnosed type 
2 diabetic patients, particularly those with a GFR >/=90 ml/min per 1.73 
m2, both CG and MDRD equations significantly underestimate eGFR. 
This highlights a limitation in the use of eGFR in the majority of diabetic 
subjects outside the setting of chronic kidney disease. 
 
There are also some situations in which the GFR estimate provided 
by a creatinine clearance test is more desirable than that based on a 
prediction equation. This is because certain individual variations (e.g., 
diet and muscle mass) are not taken into consideration in prediction 
equations. 
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 Extremes of age  
 Extremes of body size 
 Disease of the skeletal muscles  
 Vegetarian diet 
 Use of creatine (dietary) supplements  
 Rapid changes in kidney function  
 Amputation 
 Malnutrition  
 Muscle wasting  
 Pregnancy” 
 
Cystatin C : 
“Cystatin C is found in most cells, is filtered from the circulation 
by the glomeruli and forms a fluid filtrate.37 The cystatin C left in the 
filtrate is then reabsorbed by the body and not returned to the blood. In 
Renal dysfunction the cystatin C levels in blood increases, and the test 
can reflect the reduction in the formation of fluid filtrate. The increased 
levels of cystatin C may be detected before there is a decrease in the 
GFR.” In addition, gender, muscle mass and race or ethnicity does not 
influence the test.  
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 In general, “an estimated GFR ≥ 90 millilitres per minute per 1.73 
square meters (mL/min/1.73 m²) is normal. The 1.73 m² value represents 
the average adult body surface area in square meters. An estimated GFR 
less than 90 mL/min/1.73 m² is abnormal.” 
 
In addition to aging and kidney disease, there are several other 
factors that may affect GFR. 
 
Fig14.  Factors affecting the GFR : 
 
 
42 
 
Table 5. Disease conditions affecting GFR  
 
“Conditions  that can decrease GFR:  
 Vascular disease 
 Congestive heart failure   
 Sodium and water depletion  
 Haemorrhage & shock  
 Vigorous exercise” 
 
Conditions  that can increase GFR:  
 Dietary protein intake 
 Ketoacidosis 
 Hyperglycemia  
 Pregnancy  
 
PROTEIN TOLERANCE TEST38 
 “In  this  test,  a  patient  is  exposed  to  high  level  of  protein  
and GFR is calculated in a span of two-three days, normally the GFR 
should increase by 20% without protein leaking into the urine.. The 
severity and prognosis of the renal disease is often predicted on basis of 
GFR.”  
A direct relationship was also found between the protein intake 
and GFR, i.e., “with an increase in protein intake there was an increase 
in GFR in both short term and long term studies. The possibility of a 
variation in GFR and the capacity of kidney to augment its level of 
function suggest a renal functional reserve40.”  
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Fig 15.  Changes in GFR after Protein meal  
 
 
Renal Functional Reserve: 
“The renal functional reserve represents the capacity of the kidney 
to increase its level of operation under certain demands. When the 
kidneys are subjected to greater physiological demands, they also 
respond with an increase in GFR.” 
 
In renal diseases, this functional reserve increases GFR of the 
residual nephrons, replacing the lost function and maintaining the whole 
organ GFR.41 Only after the residual nephrons can no longer compensate 
for the functional loss, will the changes in resting GFR and rise in serum 
creatinine occur. On the other hand, the patient with a renal disease on a 
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low protein diet may have a reduction in GFR unrelated to the 
progression of renal disease. Resting GFR therefore is not only an 
insensitive index for early detection of renal disease but is also 
inappropriate for renal disease follow up.  
 
 Glucose tolerance test (GTT) has been used to assess the 
patient at risk of diabetes mellitus. The stress of glucose load in GTT 
unravels the patient with marginal pancreatic dysfunction. It has been 
suggested that analogous to GTT, a Protein Tolerance Test (PTT) may 
help in identifying individuals with subnormal renal function before they 
manifest clinically. The stress of PTT will enable us to determine 
individuals with impaired functional reserve.42 Thus PTT is a better test 
than resting GFR or serum creatinine 
 
Mechanisms of renal hemodynamic response to protein feeding43. 
  An acute oral protein load causes a transient hyper filtration 
that might reveal a loss of glomerular permeable selectivity properties. A 
protein meal, on digestion, “which acutely raises the plasma amino acid 
concentration similar to intravenous amino acid infusion. In a healthy 
metabolic state, the glomerulus filters these amino acids and acts directly 
on the kidney to stimulate proximal tubular absorption. Amino acid may 
also change sensitivity of the macula densa sensing mechanisms by 
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altering cell permeability. Sensing a reduced tubular sodium chloride 
concentration, the macula densa cells release EDRF and prostaglandins 
locally, which cause afferent arteriolar vasodilatation. This afferent 
vasodilatation results in increased blood flow and GFR.” 
Fig 16.  Mechanism of renal response to Protein load 
 
 
 
Utility of the protein tolerance test in clinical nephrology:  
 
 “The protein tolerance test can be utilized in: 
 a. Assessing the baseline and progression of renal disease in certain 
high risk groups –like diabetics, hypertensives, polycystic kidney disease 
patients, and patients with a solitary kidney. These patients can be 
accurately prognosticated and planned for more aggressive intervention if 
required, by testing with stress GFR as compared to resting GFR.  
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 b. Assessment of borderline donors. Due to shortage of live related 
donors, elderly and hypertensive individuals are now being taken up as 
potential renal donors. Stress GFR in at least these high risk donors will 
be desirable to reject those who are likely to have renal compromise 
subsequently, though they might be having a normal resting GFR.” 
 
Procedure for conducting PTT44 : 
The protein tolerance test has two components: 
1. Stress GFR  
2. Tubular stress test  
 
STRESS GFR 
 “As described by Bosch et al42, Patients should be fasting and 
should receive oral hydration with 20 ml/kg of water. Once hydration is 
complete, urine volume is replaced by an equal quantity of water. 
Endogenous creatinine clearance is used for assessing the test and 
baseline GFR. Baseline GFR– Two blood samples are collected for serum 
creatinine measurement at the start and 30 minutes apart for calculation 
of creatinine clearance by Cockcroft and Gault equation (CG formula) 
and the mean is taken as baseline creatinine clearance.” 
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TUBULAR STRESS TEST:  
 
  “Herrena et al 45 assessed the functional reserve of the 
kidney by performing tubular function. It is documented that, Increase in 
tubular secretion of creatinine (TScr) after a test meat meal. They 
demonstrated that in normal individual TScr was three times the baseline, 
while patients with moderate renal failure were unable to raise their 
TScr.” However, it requires standardization and further studies needed to 
prove its utility. 
 
INTERPRETATION:  
   In normal individuals, protein tolerance test will show 
an increase in GFR from baseline in absence of urinary protein. In 
contrast, those with abnormal test will have proteinuria and no increase in 
GFR. The maximal filtration capacity attained after the protein load in 
various western studies is reported to be around 140 -160 ml/min/1.73 m2 
with a percentage increase in GFR of 20 - 40% from basal state2, 3, 5. 
Increase in GFR without any proteinuria suggests normal response, while 
increase in GFR with proteinuria would suggest renal injury and no 
increase in GFR would suggest incipient renal failure.  
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 Hence, protein tolerance test can be used to ascertain an 
individual’s renal reserve, with incipient renal failure even though with 
Normal GFR and serum creatinine. Thus, appropriate measures can be 
initiated at the earliest in such cases. Not much literature is available at 
the moment in relation to this test. In India, only two studies have 
evaluated the protein tolerance test and proved that protein tolerance test 
was a useful tool in identifying at risk patients. 
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MATERIALS AND METHODS: 
 
   This study was conducted in Government Royapettah 
hospital, Chennai for a duration of 6 months from April 2015 to Sep 2015. 
A proper ethical approval was obtained from the Institutional Ethical 
Committee .The study was conducted after getting informed consent from 
all the Subjects involved in this study.  
 
Study Design                   :   Cross Sectional Comparative Study  
Collaborating Depts.  :  Diabetology, Biochemistry, 
                                                    And Master Health Check up  
Study Period                    :         6 months (April 2015 to Sep 2015) 
Conflict of Interest          :         Nil 
 
Study population:  
                              
    Patients attending Diabetology outpatient 
department will be included in the study. An equal number of Healthy, age 
and sex matched subjects without diabetes or its complications, who are 
undergoing Master Health Check up will be included in the study for 
comparison.  
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Inclusion Criteria: 
 Patients with type 2 diabetes mellitus 
 Healthy, age and sex matched subjects without diabetes or its 
complications, who are also included in the study for comparison. 
 
Exclusion Criteria: 
 Type 2 diabetes mellitus with Proteinuria 
 Systemic hypertension 
 Renal Failure 
 
 Diagnosis of Type 2 diabetes mellitus was made by clinical records 
and blood investigations including fasting and postprandial blood glucose 
values. The WHO criteria were employed for the diagnosis of diabetes 
mellitus.2 
 
 The presence of absence of renal dysfunction was made on the basis 
of the following: 
1. Clinical details  
2.  Investigations – Sr. Creatinine, creatinine clearance, Spot urinary 
protein   estimation 
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SAMPLE SIZE:                     104 (52 cases + 52 controls) 
  According to this formula: 
 
 
 
p (Prevalence of kidney disease in Type 2 Diabetes) =40%   
d (absolute Precision) = 10%) 
Assuming alpha error = 5%,  
 
Methodology: 
               After obtaining informed written consent, basic 
demographic details, detailed clinical history and physical examination 
will be done. Base line Fasting Blood sample for Serum Creatinine, Blood 
Glucose and urine sample for PCR will be collected.  
 
                     Then study population were subjected to a “Protein 
Tolerance Test” using protein meal -100 gm of protein as cottage cheese. 
After giving high protein meal, Blood samples were collected at 60 and 
120 minutes for serum creatinine and Urine samples were collected at 120 
mins for Urine PCR measurement.   
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 To assess the Renal Functional Reserve, by e GFR was calculated 
by using   Cockcroft-Gault Equation: 
 
 
 
INTERPRETATION OF RESULTS:  
1. Urine PCR :  
i. Normal         :-  ≤ 20 mg  
ii. Abnormal     :-  ≥ 20 mg  
2. Renal Function:  
i. Normal             :-    Increase in GFR without any proteinuria  
ii. Renal injury     :-    Increase in GFR with proteinuria  
iii. Renal failure      :-   No increase in GFR with proteinuria  
 
DATA COLLECTION &   ANALYSIS: 
 
  The data of each patient will be collected on a proforma 
specially designed for this study and which includes demographic details, 
past medical history, diabetic profile and renal functional reserve before 
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and after Protein Tolerance test. The information collected regarding all 
the selected subjects were recorded in a Master Chart.  
 
  The collected data was analyzed to identify the percentage of 
incipient renal failure in patients with normal GFR and normal serum 
creatinine in Type 2 Diabetes patients and compared with normal 
population by using SPSS for windows, version 16.0, Chicago Inc.  
 
  To describe about the data descriptive statistics frequency 
analysis, percentage analysis were used for categorical variables and the 
mean & S.D were used for continuous variables. The normality of the data 
was verified with “Shapiro Wilk's test” for normality showed the data is 
normal. To find the significant difference between the bivariate samples in 
Paired groups “Paired sample t-test” was used & for Independent groups 
the “unpaired sample t-test” was used. For repeated measures the 
“Repeated measures of ANOVA” with adjustment for multiple 
comparisons to control the type I error, the “Bonferroni test” was used. To 
find the significance in categorical data “Chi-Square test” was used. In all 
the above statistical tools the probability value 0.05 is considered as 
significant level.  
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RESULTS AND STATISTICAL ANALYSIS 
 
 STUDY POPULATION:  
   
  Majority of the study subjects were from in and around 
Chennai city urban population. The total number of study population 
included in the study was 104. Among them 52 are cases and 52 controls 
were also included in the study for comparative analysis.  
 
 
AGE DISTRIBUTION: 
   
  The age of the controls ranged from 35 to 69 years with a 
mean age of 51.7 years. The age of the patients in the cases ranged from 
32-67 years with a mean of 53.9 years. Among  the cases, 2 patients were 
in the age group of up to 40 years (3.8%) , 14 patients in 41-50 age group 
(26.9%), 29 patients in 51-60 age group (55.8%),7 patients (13.5%) were 
in the age group of >60years. 
 The age groups of the cases and controls were comparable and 
there was no statistical difference (p=0.089)     
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TABLE 6: AGE DISTRIBUTION 
Age Range Number  CASES CONTROLS Total 
Up to 40 yrs 
Count 2 9 11 
%  3.8% 17.3% 10.6% 
41 - 50 yrs 
Count 14 17 31 
%  26.9% 32.7% 29.8% 
51 - 60 yrs 
Count 29 22 51 
%  55.8% 42.3% 49.0% 
Above 60 yrs 
Count 7 4 11 
%  13.5% 7.7% 10.6% 
Total Count 52 52 104 
"p" value - 0.089 (Not significant)   
 
GENDER DISTRIBUTION:  
 In the study population among the cases 23 are females and 29 are 
males and among the controls 25 are females and 27 males. 
TABLE 7: GENDER DISTRIBUTION 
GENDER Number  CASES CONTROLS Total  
Female  
Count 23 25 48 
%  44.2% 48.1% 46.2% 
Male 
Count 29 27 56 
%  55.8% 51.9% 53.8% 
Total Count 52 52 104 
"p" value - 0.694 (Not significant)   
 
 The gender of the patients and controls were comparable and 
there was no statistical difference (p=0.694)     
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TABLE 8:  Quantitative parameters 
 
Variable 
Renal 
Function  
Number Mean S .D 
‘p’ 
value 
Significance 
Age 
Failure 12 59.75 5.848 
0.0001 
Highly 
significant 
Injury 9 57.89 5.278 
Normal 31 50.52 6.678 
Total 52 53.92 7.470 
Duration of 
DM in yrs 
Failure 12 11 1.603 
0.0001 
Highly 
significant 
Injury 9 7 1.323 
Normal 31 5 .995 
Total 52 6.46 2.845 
PPBG-2hr 
Failure 12 294.00 35.481 
0.0001 
Highly 
significant 
Injury 9 296.89 36.412 
Normal 31 226.10 31.448 
Total 52 254.02 47.282 
S.Cr (0 min) 
Failure 12 .9125 .12636 
0.728 
Not        
Significant  
Injury 9 .8722 .16604 
Normal 31 .9048 .10516 
Total 52 .9010 .12025 
S.Cr 
(60Min) 
Failure 12 1.0167 .13371 
0.001 Significant 
Injury 9 .8333 .18028 
Normal 31 .8484 .12075 
Total 52 .8846 .15131 
S.Cr 
(120Min) 
Failure 12 .9250 .14848 
0.0001 
Highly 
significant 
Injury 9 .7556 .16667 
Normal 31 .6452 .10276 
Total 52 .7288 .16959 
e GFR1 
Failure 12 69.7667 8.96028 
0.466 
Not        
Significant  
Injury 9 70.9911 7.45399 
Normal 31 73.0787 8.13799 
Total 52 71.9531 8.18826 
e GFR 2 
Failure 12 65.9433 10.34144 
0.0001 
Highly 
significant 
Injury 9 77.5778 9.64677 
Normal 31 88.3065 11.57919 
Total 52 81.2888 14.29358 
Mean S.Cr1 
Failure 12 .9125 .12636 
0.728 
Not        
Significant  
Injury 9 .8722 .16604 
Normal 31 .9048 .10516 
Total 52 .9010 .12025 
Mean S.Cr2 
Failure 12 .9708 .13561 
0.0001 
Highly 
significant 
Injury 9 .8000 .15811 
Normal 31 .7484 .08610 
Total 52 .8087 .14373 
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BMI :  
 Study population were classified as overweight(≥25), normal 
weight(18.5-24.5) and underweight(≤18.5) according to the Body Mass 
index(kg/m2).Out of 52 controls, 13 were in the underweight group(25%), 
27 were in the normal weight group (51.9%) and12 were (23.1 %) in the 
overweight group. Out of 52 cases, 14 were in the underweight group 
(26.9%) were in, 25 were in the normal weight group (48.1%) and 13 were 
in the overweight group (25%). 
 
TABLE 9:  BMI and Study Population 
BMI Number  CASES CONTROLS Total 
Normal 
Count 25 27 52 
%  48.1% 51.9% 50.0% 
Over weight 
Count 13 12 25 
%  25.0% 23.1% 24.0% 
Under weight 
Count 14 13 27 
%  26.9% 25.0% 26.0% 
Total Count 52 52 104 
"p" value - 0.926 (Not significant)   
 
The mean height, weight and BMI of the patients and controls 
were comparable and there was no statistical difference (p values are 
0.907, 0.834 & 0.926 respectively). 
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BLOOD GLUCOSE: 
    Fasting (0 hr) and postprandial (2 hrs) blood glucose values 
were analyzed in the two groups. The mean FPG in control group was 
90.4 mg/dl compared to 155.6 mg/dl in the cases. On the other hand mean 
2 hour PPG values in control group were 129.1mg/dl as opposed to 
254.1mg/dl in the cases.  
 Both the Fasting and Post prandial Blood Glucose values of the 
cases and controls were comparable and statistically significant (p 
values are 0.0001 & 0.0001 respectively) 
 
SERUM CREATININE:  
  Serum creatinine @0 min and post protein load Serum 
creatinine levels @ 60, 120 min & mean were analyzed. The Serum 
creatinine @ 0 min values were 0.86 mg/dl in control group, 0.90 mg/dl in 
cases group. The difference between the two groups was statistically not 
significant (p=0.079). 
 
  The mean post protein load Serum creatinine @ 60 min and 
120 min values were 0.76mg/dl and 0.65 mg/dl in control group, 
0.88mg/dl and 0.73 mg/dl in the cases group respectively. The difference 
between the two groups was statistically significant (p values are 
0.0001 & 0.005 respectively)  
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  The post protein load mean Serum creatinine values were 0.7 
mg/dl in control group, 0.81 mg/dl in cases group. The difference 
between the two groups was statistically significant (p=0.0001). 
e-GFR :  
  The e GFR-1 mean value was 76.83 in the control group 
compared to 71.95 in the cases .The difference between the two groups 
was statistically significant (p=0.016). 
  The e GFR-2 values remained persistently decreased with a 
mean of 95.38 in the control group compared to 81.28 in the study group 
.The difference between the two groups was statistically significant 
(p=0.0001). 
Urine Protein Creatinine Ratio (PCR):  
 
 Urine PCR was analyzed in the two groups at 0 min and 120 min 
after protein meal .The results are summarized in table 4 & 5. 
TABLE 10:  Urine PCR 0 min and Study Population 
Urine PCR (0 min) CASES CONTROLS Total 
Abnormal 0 0 0 
Normal  52 52 104 
Total 52 52 104 
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TABLE 11:  Urine PCR @120 min and Study Population:  
 
Urine PCR (120 
min) 
Number  CASES CONTROLS Total 
Abnormal 
Count 21 2 23 
%  40.4% 3.8% 22.1% 
Normal  
Count 31 50 81 
%  59.6% 96.2% 77.9% 
Total Count 52 52 104 
"p" value - 0.0001 (Highly significant)   
 
 Urine PCR was normal @ 0 min in the both the groups. Urine PCR 
@120 min was higher (Abnormal) in the cases group than the control 
group, which was statistically significant (p=0.0001). 
 
RENAL FUNCTION ANALYSIS: 
 Renal function was analyzed in the two groups. Normal Renal 
Function was observed in 50 patients (96.2%) in the control group 
compared to 31 patients (59.6%) in the cases. Renal injury was observed 
in 2 patients (3.8%) in the control group compared to 9 patients (17.3%) in 
the cases group. Renal Failure was observed in none of the patients in the 
control group compared to 12 patients (23.1%) in the cases group. The 
prevalence of Renal dysfunction was more in the study group (40.4%) 
compared to 3.8 % in controls and the difference was statistically 
significant (p=0.0001). The results are shown in table 6.   
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TABLE 12:  RENAL FUNCTION 
 
Renal Function Number  CASES CONTROLS Total 
Failure  
Count 12 0 12 
%  23.1% 0.0% 11.5% 
Injury  
Count 9 2 11 
%  17.3% 3.8% 10.6% 
Normal 
Count 31 50 81 
%  59.6% 96.2% 77.9% 
Total Count 52 52 104 
"p" value - 0.0001 (Highly significant)   
 
 
AGE AND RENAL FUNCTION:  
 
 The relation between age and renal function was analyzed. It was 
found that renal failure was more in patients over 60 years (50%) as 
compared to 41.7% in the 51-60 years group, 8.3% in the 41-50 years 
group and none in the < 40yrs of age. The difference was found to be 
statistically significant (p=0.001). 
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TABLE 13: AGE AND RENAL FUNCTION 
Age Range Number 
Renal Function 
Total 
Failure  Injury Normal 
Up to  
40 yrs 
Count 0 0 2 2 
%  0.0% 0.0% 6.5% 3.8% 
41 - 50 yrs 
Count 1 1 12 14 
%  8.3% 11.1% 38.7% 26.9% 
51 - 60 yrs 
Count 5 7 17 29 
%  41.7% 77.8% 54.8% 55.8% 
Above 
 60 yrs 
Count 6 1 0 7 
%  50.0% 11.1% 0.0% 13.5% 
Total Count 12 9 31 52 
"p" value - 0.001 (Highly significant)   
 
 
SEX AND RENAL FUNCTION: 
   
  The relation between sex and renal function was analyzed. It 
was found that renal failure was more in patients in males (58.3%) as 
compared to 41.7% in the females and injury also  more in patients in 
males (55.3%) as compared to 44.4% in the females .But the difference 
was not statistically significant (p=0.979) 
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TABLE 14:  SEX AND RENAL FUNCTION 
SEX Number 
Renal Function 
Total 
Failure  Injury Normal 
Female  
Count 5 4 14 23 
% 41.7% 44.4% 45.2% 44.2% 
Male  
Count 7 5 17 29 
%  58.3% 55.6% 54.8% 55.8% 
Total Count 12 9 31 52 
"p" value - 0.979 ( Not significant)   
 
BMI AND RENAL FUNCTION: 
 
TABLE 15:  BMI AND RENAL FUNCTION: 
BMI Number 
Renal Function 
Total 
Failure  Injury Normal 
Normal 
Count 6 3 16 25 
%  50.0% 33.3% 51.6% 48.1% 
Overweight 
Count 4 3 6 13 
%  33.3% 33.3% 19.4% 25.0% 
Underweight 
Count 2 3 9 14 
%  16.7% 33.3% 29.0% 26.9% 
Total Count 12 9 31 52 
"p" value – 0.711 ( Not significant)   
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DURATION OF DISEASE AND RENAL FUNCTION: 
 The relation between duration of disease and renal dysfunction was 
analyzed. It was seen that 7 out of 12 patients (58.3%) with a longer 
duration of disease (>10 years) had renal failure compared to 5 out of 13 
patients (41.7%) with duration of disease between 5-10 years. None of the 
patients with duration of disease <5 years had renal failure. The values are 
summarized in table 10. The difference was found to be statistically 
significant (p=0.0001). 
 
TABLE 16: DURATION OF DISEASE AND RENAL FUNCTION 
Duration of 
DM  
Number 
Renal Function 
Total 
Failure  Injury Normal 
< 5 yrs 
Count 0 0 14 14 
%  0.0% 0.0% 45.2% 26.9% 
5 - 10 yrs 
Count 5 9 17 31 
%  41.7% 100.0% 54.8% 59.6% 
> 10 yrs 
Count 7 0 0 7 
%  58.3% 0.0% 0.0% 13.5% 
Total Count 12 9 31 52 
"p" value - 0.0001 (Highly significant)   
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URINE PCR  AND RENAL FUNCTION:  
 Analysis was done in relation to urine PCR and renal dysfunction. It 
was found that abnormal urine PCR was seen in 21 patients at 120 minutes 
compared to none at 0 minutes. 12 out of these 21 patients had renal 
failure and 9 out of 21 patients had renal injury. The results are presented 
in the following table 11. The difference was found to be statistically 
significant (p=0.0001). 
 
TABLE 17: URINE PCR  AND RENAL FUNCTION 
Urine PCR 
(120 min) 
Number 
Renal Function 
Total 
Failure  Injury Normal 
Abnormal  
Count 12 9 0 21 
% 100.0% 100.0% 0.0% 40.4% 
Normal 
Count 0 0 31 31 
%  0.0% 0.0% 100.0% 59.6% 
Total Count 12 9 31 52 
"p" value - 0.0001 (Highly significant)   
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QUANTITATIVE PARAMETERS AND RENAL FUNCTION:  
  The results of Quantitate parameters and Renal Function are 
summarized in the following table 12. 
Table 18: QUANTITATIVE PARAMETERS AND RENAL FUNCTION 
Variable 
Renal 
Function  
Number Mean S .D 
‘p’ 
value 
Significance 
Age 
Failure 12 59.75 5.848 
0.0001 
Highly 
significant 
Injury 9 57.89 5.278 
Normal 31 50.52 6.678 
Total 52 53.92 7.470 
Duration of 
DM in yrs 
Failure 12 11 1.603 
0.0001 
Highly 
significant 
Injury 9 7 1.323 
Normal 31 5 .995 
Total 52 6.46 2.845 
PPBG-2hr 
Failure 12 294.00 35.481 
0.0001 
Highly 
significant 
Injury 9 296.89 36.412 
Normal 31 226.10 31.448 
Total 52 254.02 47.282 
S.Cr (0 min) 
Failure 12 .9125 .12636 
0.728 
Not        
Significant  
Injury 9 .8722 .16604 
Normal 31 .9048 .10516 
Total 52 .9010 .12025 
S.Cr 
(60Min) 
Failure 12 1.0167 .13371 
0.001 Significant 
Injury 9 .8333 .18028 
Normal 31 .8484 .12075 
Total 52 .8846 .15131 
S.Cr 
(120Min) 
Failure 12 .9250 .14848 
0.0001 
Highly 
significant 
Injury 9 .7556 .16667 
Normal 31 .6452 .10276 
Total 52 .7288 .16959 
e GFR1 
Failure 12 69.7667 8.96028 
0.466 
Not        
Significant  
Injury 9 70.9911 7.45399 
Normal 31 73.0787 8.13799 
Total 52 71.9531 8.18826 
e GFR 2 
Failure 12 65.9433 10.34144 
0.0001 
Highly 
significant 
Injury 9 77.5778 9.64677 
Normal 31 88.3065 11.57919 
Total 52 81.2888 14.29358 
Mean S.Cr1 
Failure 12 .9125 .12636 
0.728 
Not        
Significant  
Injury 9 .8722 .16604 
Normal 31 .9048 .10516 
Total 52 .9010 .12025 
Mean S.Cr2 
Failure 12 .9708 .13561 
0.0001 
Highly 
significant 
Injury 9 .8000 .15811 
Normal 31 .7484 .08610 
Total 52 .8087 .14373 
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CHARTS: 
 
Chart 1. Gender Distribution  
 
 
 
Chart 2. Age Distribution  
 
70 
 
Chart 3.  Weight in study population:  
 
 
 
Chart 4. BMI in study population:  
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Chart 5. Fasting blood Glucose levels in study population: 
 
 
 
 
Chart 6 .Post prandial blood Glucose levels in study population: 
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Chart 7.  Serum Creatinine levels in study population: 
 
 
 
Chart 8 .e-GFR levels in study population: 
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Chart 9. Urine PCR levels in study population: 
 
 
 
Chart 10 .Renal function in study population: 
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Chart 11.Renal function in cases 
 
 
 
Chart 12. BMI and Renal function in cases 
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Chart 13. Gender and Renal function in cases 
 
 
 
Chart 14. Age and Renal function in cases 
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Chart 15. Duration of DM and Renal function in cases 
 
 
 
 
Chart 16. Urine PCR  and Renal function in cases 
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Chart 17. Sr. Creatinine and Renal function in cases 
 
 
 
Chart 18.e-GFR and Renal function in cases 
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DISCUSSION 
 
  Diabetes remains a common menace in the developing 
population and the number has been increasing at an alarming rate in the 
recent years. The key to successful prevention of complications lies in 
early diagnosis and control. “The United Kingdom Prospective Diabetes 
Study, conducted from 1976 to 1997, showed conclusively that, in people 
with improved blood glucose control, the risk of early kidney disease was 
reduced by a third.” Several studies conducted over the past decades have 
clearly do that, “any intervention resulting in sustained lowering of blood 
glucose levels will be beneficial to patients in the early stages of CKD.” 
   
  Despite adequate control of diabetes, patients may land up 
with one or more of the macro vascular or micro vascular complications. 
Diabetic nephropathy is a common problem and it remains one of the 
challenges for us to find the renal dysfunction at an initial stage. Early 
diagnosis of renal dysfunction in diabetic patients would allow us to 
initiate Reno protective measures at an early to prevent the progression of 
kidney disease and decrease the morbidity and mortality. 
 
  The early diagnosis of renal dysfunction is a challenge 
because the renal system has considerable functional reserve so that 
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routine biochemical tests for renal function can only detect abnormalities 
once more than 66% of functioning renal tissue has been lost. Precise 
evaluation of renal function would also allow more effective monitoring of 
the rate of decline of renal function over time and help determine the 
efficacy of a therapeutic intervention. 
 
  Many of the results in this study correlated well with 
literature. There was an age related decline in GFR similar to that seen in 
most studies in the past. Around 85% of patients in this study above 60 
years had renal failure compared to only 13% in age group <60 years. The 
following graph shows the age related decline in GFR as studied in the 
MDRD study. This was as a result of natural history of renal disease as 
well as increase in conditions like diabetes and hypertension 
Fig 17.   Age-associated decline in estimated GFR 
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  It was found in our study that increase in duration of diabetes 
was strongly related to renal failure. This is well in concurrence with the 
study done by coulhon et al where it was seen that “advancing age and 
duration of diabetes were associated with renal failure in Type 2 and Type 
1 diabetes. In Type 2 diabetes duration of diabetes was a more important 
risk factor than age.” 
 
   In the same study, diabetic retinopathy and proteinuria were 
strongly associated with renal failure in both Type I and Type II diabetes 
mellitus. This was also seen in our study where 57% of patients with 
abnormal urine PCR had renal failure. 
 
  The protein tolerance test is an upcoming investigation and 
has not been extensively evaluated in the past. Very few studies have 
utilized this test to identify patients at risk of renal dysfunction. 
 
  Protein tolerance test was developed way back in 1950 by 
Horn et al where they proved that PTT could identify early onset diabetic 
nephropathy based on the fact that protein loading could exert a stress on 
both the glomeruli and tubules. Subsequently no major study has been 
done with regard to PTT. In this study it was seen that the mean 
creatinine- 2 values (post protein challenge) were more in patients with 
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renal failure compared to those with renal dysfunction and normal renal 
function. The decline in eGFR-2 (post protein challenge) was also 
statistically significant (65.9 in renal failure versus 88.3 in normal renal 
function) implying that this could be a useful marker of renal reserve. 
Though there are no major studies for comparison, the results of the study 
were quite significant statistically. This can be done on a larger scale to 
prove the utility of the protein tolerance test. 
 
  Protein tolerance test may be very useful test to diagnose the 
incipient renal failure in a person with normal serum creatinine and 
creatinine clearance and these patients who are most likely to be benefited 
by an early aggressive intervention. This is more important in evaluating 
in persons with high risk factors like hypertension, diabetes mellitus, 
polycystic kidney disease and post- renal transplants. PTT can also be 
used to check the borderline renal donor, and to give accurate 
prognostication in a progressive renal disease. Tubular stress test still 
requires standardization and further studies need to prove its utility. 
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SUMMARY 
  The study on “Assessment of Renal Functional Reserve by 
Protein Tolerance Test in Type 2 Diabetes Mellitus” was undertaken to 
find out the usefulness of protein tolerance test in detecting patients with 
type 2 diabetes mellitus who were at risk of developing renal dysfunction. 
  
  The present study was a cross sectional comparative study 
done at Govt. Royapettah Hospital Chennai. After institutional Ethical 
Committee clearance, 52 patients with type 2 diabetes mellitus and 52 
healthy controls were selected according to the inclusion criteria. There 
were almost equal males and females in the study. A baseline fasting and 
post prandial blood sugar, urine PCR ,serum creatinine and baseline GFR 
was calculated. This was followed by a protein challenge with 100 grams 
of protein food. Serum creatinine and GFR were measured at 60 and 120 
minutes after protein challenge.  
  
  Using statistical data, correlation was analyzed between 
pre/post protein challenge serum creatinine in cases and controls in 
relation to GFR and renal function. It was found that patients with renal 
failure had more persistent elevation of serum creatinine and sustained 
decrease in GFR as compared to patients with normal renal function or 
those with mild renal dysfunction. There was also an age related decline in 
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renal function. Proteinuria was found to be an independent risk factor for 
renal failure. 
 It was also found that patients with long duration of diabetes and 
poor glycaemic control have more chance of early renal injury and 
dysfunction than those with short duration of diabetes and good glycaemic 
control. 
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CONCLUSION 
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CONCLUSIONS 
 
1. Renal damage starts in Diabetic patients even before microalbuminuria and 
clinical nephropathy starts.  
 
2. It was found that longer the Duration of diabetes, more the chance of renal 
injury and dysfunction.  
 
3. Renal injury and dysfunction directly correlates with poor metabolic control.  
 
4. Protein tolerance test may be a very helpful test to diagnose occult renal 
failure in patients with normal serum creatinine and normal GFR values.  
 
5. Identifying those patients with subnormal renal function may enable us to 
initiate an early aggressive intervention.  
 
6. This Protein Tolerance Test may be very much useful in high risk patients 
like Diabetics, Hypertensive patients.  
 
7. Patients with diseases like solitary kidney, polycystic kidney disease, post 
renal transplants can also be subjected to this test to identify incipient renal 
failure.  
 
8. Protein Tolerance Test can also be used to check the borderline renal donor in 
order to give accurate prognostication in a progressive renal disease.  
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PLAGIARISM CERTIFICATE 
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PLAGIARISM DIGITAL RECEIPT 
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PROFORMA 
 
PERSONAL DETAILS: 
NAME :   ID:    ADDRESS: 
AGE:     
SEX: 
Height:    Weight:  BMI: 
Medical History: 
Diabetes: Yes/No     Duration of DM: 
Hypertension: yes / no    Renal Disease: yes /no  
Diabetic Nephropathy: yes / no 
Diet History: veg /Non veg:    Drug History:    
Personal History:     Family History: 
Physical examination: 
Pulse:    BP:    Temp:    RR: 
CVS:   RS:                               ABDOMEN:  CNS: 
Investigations: Blood Sugar: FBG:   2hour PPBG: 
Protein Tolerance Test: 
Serum Creatinine:  
Fasting:    e GFR1: 
After Protein Meal @60min:   120min:  mean:   e GFR2: 
Urine PCR:  0min:               120min:            
Renal Function Result: (Tick) 
No Evidence of Renal Dysfunction       - Normal  (N) 
Evidence of Renal injury               - Injury      (I) 
Evidence of incipient Renal Failure      - Failure    (F) 
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INFORMED CONSENT FORM 
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ETHICAL COMMITTEE APPROVAL CERTIFICATE 
 
